why choose us

First received: November 03, 2023

Clinical Trial: Open Label, 6-month Study for High Frequency and Chronic Migraine,

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Migraine, Headache

Study Type: OBSERVATIONAL


Official Title: A Multi-Center Unblinded Proof-of-Concept Study of DaxibotulinumtoxinA for Migraine Prevention in High-Frequency and Chronic Migraine: the Standard Paradigm

Brief Summary: This is a prospective, multi-center, unblinded study in patients with migraine (? 8 MMDs/month) requiring preventive treatment.Enrolled patients will receive DAX administered subcutaneously using an established, published, legacy injection paradigm (referred to herein as the "standard paradigm").The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase.

Read more